Background.Visual analog scale (VAS) scores are used as global quality-of-life indicators and, unlike true utilities (which assess the desirability of health states v. an external metric), are often collected in HIV-related clinical trials. The purpose of this study was to derive and evaluate transformations relating aggregate VAS scores to utilities for current health in patients with HIV/AIDS.Methods.HIV-specific transformations were developed using linear and nonlinear regression to attain models that best fit mean VAS and standard gamble (SG) utility values directly derived from 299 patients with HIV/AIDS participating in a multicenter study of health values. The authors evaluated the transformations using VAS and SG utility values derived directly from patients in other HIV/AIDS studies. Derived transformations were also compared with published transformations.Results.A simple linear transformation was derived (u = 0.44v + 0.49), as was the exponent for a curvilinear model (u = 1-[1- v]1.6), where u =the sample mean utility and v the sample mean VAS score. The curvilinear transformation predicted values within 0.10 of the actual SG utility in 5 of 8 estimates and within 0.05 in 3 of 8 estimates (absolute error ranged from -0.01 to +0.21). The linear transformation performed some-what better, predicting within 0.10 of the actual SG value in 6 of 8 cases and within 0.05 in 5 of 8 estimates (absolute error ranged from -0.05 to +0.13). An alternative linear model (u =v +0.018) derived from the literature performed similarly to our linear model (7 of 8 predictions within 0.10, 1 of 8 estimates within 0.05, and absolute error ranging from -0.15 to +0.10), whereas an alternative published curvilinear model (u =1 - [1 - v]2.3) performed the least well (2 of 8 estimates within 0.10 of the actual values and no estimates within 0.05).Conclusions.Predicted utilities are a reasonable alter-native for use in HIV/AIDS decision analyses and costeffectiveness analyses. Linear transformations performed better than curvilinear transformations in this context and can be used to convert aggregate VAS scores to aggregate SG values in large HIV/AIDS studies that collect VAS data but not utilities.
Get full access to this article
View all access options for this article.
References
1.
1. Torrance GW. Measurement of health state utilities for economic appraisal . J Health Econ. 1986;5: 1-30 .
2.
2. Torrance GW. Utility approach to measuring health-related quality of life . J Chronic Dis. 1987;40: 593-603 .
3.
3. Tsevat J. What do utilities measure? Med Care. 2000;38: II160-II164 .
4.
4. Stiggelbout AM, Eijkemans MJ, Kiebert GM, Kievit J, Leer JW, De Haes HJ. The “utility” of the visual analog scale in medical decision making and technology assessment: is it an alternative to the time trade-off? Int J Technol Assess Health Care. 1996;12: 291-298 .
5.
5. Torrance GW. Toward a utility theory foundation for health status index models . Health Serv Res. 1976;11: 349-369 .
6.
6. Froberg DG, Kane RL. Methodology for measuring health-state preferences—II: scaling methods . J Clin Epidemiol. 1989;42: 459-471 .
7.
7. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making. 2001;21: 329-334 .
8.
8. Bleichrodt H, Johannesson M. An experimental test of a theoretical foundation for rating-scale valuations . Med Decis Making. 1997;17: 208-216 .
9.
9. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS . Med Decis Making. 2002;22: 475-481 .
10.
10. Tsevat J, Solzan JG, Kuntz KM, et al. Health values of patients infected with human immunodeficiency virus: relationship to mental health and physical functioning . Med Care. 1996;34: 44-57 .
11.
11. Tsevat J, Sherman SN, McElwee JA, et al. The will to live among HIV-infected patients . Ann Intern Med. 1999;131: 194-198 .
12.
12. Revicki DA, Wu AW, Murray MI. Change in clinical status, health status, and health utility outcomes in HIV-infected patients . Med Care. 1995;33: AS173-AS182 .
13.
13. Lenert LA, Feddersen M, Sturley A, Lee D. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection . Am J Med. 2002;113: 229-232 .
14.
14. Paltiel AD, Scharfstein JA, Seage GR, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection . Med Decis Making. 1998;18: S93-S105 .
15.
15. Freedberg KA, Scharfstein JA, Seage GR III, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections . JAMA. 1998;279: 130-136 .
16.
16. Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women . Ann Intern Med. 1999;130: 97-107 .
17.
17. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men . JAMA. 1999;281: 1822-1829 .
18.
18. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness . Ann Intern Med. 2001;134: 440-450 .
19.
19. Freedberg KA, Losina E, Weinstein MC, et al. The cost effective-ness of combination antiretroviral therapy for HIV disease . N Engl J Med. 2001;344: 824-831 .
20.
20. Paltiel AD, Goldie SJ, Losina E, et al. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus . Clin Infect Dis. 2001;32: 783-793 .
21.
21. Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults . Am J Public Health. 2001;91: 1456-1463 .
22.
22. Johri M, Paltiel DA, Goldie SJ, Freedberg KA. State AIDS drug assistance programs: equity and efficiency in an era of rapidly changing treatment standards . Med Care. 2002;40: 429-441 .
23.
23. Goldie SJ, Kaplan JE, Losina E, et al. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines . Arch Intern Med. 2002;162: 921-928 .
24.
24. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS . Med Decis Making. 2002;22: 27-38 .
25.
25. Schackman BR, Freedberg KA, Weinstein MC, et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults . Arch Intern Med. 2002;162: 2478-2486 .
26.
26. Yi MS, Mrus JM, Britto M, Tsevat J. The relationship between clinical disease severity and utilities: is there a threshold effect? 24th Annual Meeting of the Society for Medical Decision Making. Baltimore, MD; 2002.
27.
27. Lenert LA, Sturley A, Watson ME. iMPACT3: Internet-based development and administration of utility elicitation protocols . Med Decis Making. 2002;22: 464-474 .
28.
28. Mrus JM, Yi MS, Tsevat J, et al. Estimating quality of life and health utility using visual analog scale scores in the Adult AIDS Clinical Trials Group Longitudinal Linked Randomized Trials Cohort (A5001) . XIV International AIDS Conference. Barcelona, Spain; 2002: Abstract # MoPeB3247.
29.
29. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36 . J Health Econ. 2002;21: 271-292 .
30.
30. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2 . Med Care. 1996;34: 702-722 .
31.
31. Bayoumi AM, Redelmeier DA. Economic methods for measuring the quality of life associated with HIV infection . Qual Life Res. 1999;8: 471-480 .
32.
32. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium . N Engl J Med. 1998;339: 1897-1904 .
33.
33. Cunningham WE, Hays RD, Williams KW, Beck KC, Dixon WJ, Shapiro MF. Access to medical care and health-related quality of life for low-income persons with symptomatic human immunodeficiency virus . Med Care. 1995;33: 739-754 .
